IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect (PHI-05)

NCT02384395 NA COMPLETED Results posted

This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).

Details

Lead sponsor	University of North Carolina, Chapel Hill
Phase	NA
Status	COMPLETED
Enrolment	40
Start date	2015-09
Completion	2021-09-17

Conditions

• HIV
• Acute HIV Infection

Interventions

• Dolutegravir 50 mg
• Lamivudine 300 mg
• Abacavir 600 mg

Primary outcomes

• Number of Participants With Viral Load Measurement <200 Copies/mL at Week 24 — Week 24
  Total number of participants on study at Week 24 with an HIV-1 RNA level less than 200 copies/mL

Countries

United States